Breaking News Instant updates and real-time market news.

MYL

Mylan

$38.12

-0.35 (-0.91%)

13:36
10/03/16
10/03
13:36
10/03/16
13:36

Lawmakers seek explanation from Mylan CEO on EpiPen profit calculations

House Oversight and Government Reform Committee Chairman Jason Chaffetz and ranking member Elijah Cummings announced they sent a letter to Mylan CEO Heather Bresch requesting information related to the company's EpiPen profit margins. The letter reads, in part: "This week... the Committee learned that your testimony omitted key tax assumptions that affect the company's profit per pack. Specifically, neither your testimony, nor the documents Mylan produced to the Committee, clearly disclosed that the company's profit claim was calculated after factoring in the statutory U.S. tax rate... Failing to disclose tax assumptions that formed the basis for the $100 profit per pack claim, despite opportunities to do so before and during the hearing, raises questions." Reference Link

  • 07

    Oct

  • 28

    Mar

MYL Mylan
$38.12

-0.35 (-0.91%)

09/22/16
LEER
09/22/16
NO CHANGE
LEER
Outperform
No tangible outcomes likely to result from Mylan EpiPen hearing, says Leerink
Leerink analyst Jason Gerberry believes no tangible outcomes are likely to result from the House Committee Hearing on Mylan's EpiPen. Nonetheless, the analyst highlights that CEO Heather Bresch stated at the hearing that the company has invested in a new formulation of EpiPen, with a 24-month shelf life versus the current 12-month. Gerberry believes this is a relatively modest benefit and says he is skeptical the line extension will be able to preserve meaningful share if/when an AB-rated generic gets approved. The analyst reiterates an Outperform rating on the shares.
09/22/16
ARGS
09/22/16
NO CHANGE
ARGS
Mylan weakness creates good entry point, says Argus
After Mylan's stock fell 17% over the last month, Argus analyst Jacob Kilstein thinks that the stock has reached an attractive entry point, He says that the company's new generic EpiPen will cannibalize branded sales but should help it beat upcoming generic competitors. He thinks that the stock is undervalued and keeps a Buy rating on the stock.
09/23/16
BERN
09/23/16
NO CHANGE
BERN
Mylan generic Epipen to lower EPS by about 10%, says Bernstein
Bernstein analyst Aaron Gal estimates that Mylan's decision to introduce a generic version of its EpiPen will create a drag of about 10% on its EPS. After viewing the Congressional hearings on the device, Gal continues to believe that a competitor to EpiPen will hit the market before the end of 2018. He keeps a $60 price target and Outperform rating on Mylan.
09/30/16
LEER
09/30/16
NO CHANGE
Target $45
LEER
Outperform
Mylan price target cut to $45 on lower EpiPen estimates at Leerink
Leerink analyst Jason Gerberry lowered his EpiPen sales forecasts by 33-45% from 2017-2021 in light of recent company updates, including its plan to launch an authorized generic of the emergency treatment later this year. While Mylan "appears on the right side of the law" regarding the latest Medicaid rebate controversy, Gerberry believes investors should consider the risk of a future settlement related to the issue. He cut his price target on Mylan shares to $45 from $55, but keeps an Outperform rating on the stock as he sees cash flows being sufficient to justify the current price.

TODAY'S FREE FLY STORIES

CHGG

Chegg

$12.44

0.48 (4.01%)

13:25
06/23/17
06/23
13:25
06/23/17
13:25
Recommendations
Chegg analyst commentary  »

Chegg price target raised…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

13:25
06/23/17
06/23
13:25
06/23/17
13:25
General news
Energy Action: Baker-Hughes »

Energy Action:…

VRX

Valeant

$15.58

0.0801 (0.52%)

13:20
06/23/17
06/23
13:20
06/23/17
13:20
Options
Valeant expiring options active Friday »

Valeant expiring options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Aug

$NSD

NASDAQ Market Internals

13:17
06/23/17
06/23
13:17
06/23/17
13:17
Technical Analysis
NASDAQ market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

13:16
06/23/17
06/23
13:16
06/23/17
13:16
Technical Analysis
NYSE market internals summary »

Volume is below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CLLS

Cellectis

$23.15

0.25 (1.09%)

13:15
06/23/17
06/23
13:15
06/23/17
13:15
Hot Stocks
Breaking Hot Stocks news story on Cellectis 

Cellectis trading resumes…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

INFY

Infosys

$14.90

0.13 (0.88%)

13:13
06/23/17
06/23
13:13
06/23/17
13:13
Hot Stocks
Infosys says 'committed no wrongdoing, denies all allegations' in NY tax matter »

Infosys issued the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CLLS

Cellectis

$23.15

0.25 (1.09%)

13:08
06/23/17
06/23
13:08
06/23/17
13:08
Hot Stocks
Cellectis to resume trading at 1:15 pm ET »

Cellectis is scheduled to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

PTLA

Portola Pharmaceuticals

$38.25

-1.24 (-3.14%)

13:06
06/23/17
06/23
13:06
06/23/17
13:06
Hot Stocks
Portola Pharmaceuticals announces FDA approval of Bevyxxa »

Portola Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jun

  • 24

    Jun

TRIP

TripAdvisor

$35.74

-0.08 (-0.22%)

13:05
06/23/17
06/23
13:05
06/23/17
13:05
Options
TripAdvisor call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

13:05
06/23/17
06/23
13:05
06/23/17
13:05
General news
Cleveland Fed hawk Mester didn't discuss policy »

Cleveland Fed hawk Mester…

BHI

Baker Hughes

$54.55

0.025 (0.05%)

13:03
06/23/17
06/23
13:03
06/23/17
13:03
Hot Stocks
Baker Hughes reports U.S. rig count up 8 to 941 rigs »

Baker Hughes reports that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

13:00
06/23/17
06/23
13:00
06/23/17
13:00
General news
Treasury Action: upcoming supply should put a floor under short rates »

Treasury Action: upcoming…

RIO

Rio Tinto

$39.32

0.61 (1.58%)

, GLNCY

Glencore

$7.10

0.05 (0.71%)

12:59
06/23/17
06/23
12:59
06/23/17
12:59
Hot Stocks
Rio Tinto to give new Glencore C&A proposal 'appropriate consideration' »

Rio Tinto (RIO)…

RIO

Rio Tinto

$39.32

0.61 (1.58%)

GLNCY

Glencore

$7.10

0.05 (0.71%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CLLS

Cellectis

$23.15

0.25 (1.09%)

12:56
06/23/17
06/23
12:56
06/23/17
12:56
Hot Stocks
Cellectis announces Calyxt filing of registration statement for proposed IPO »

Cellectis S.A. announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

PX

Praxair

$133.62

1.15 (0.87%)

12:50
06/23/17
06/23
12:50
06/23/17
12:50
Options
Call spread in Praxair may add to existing bullish position »

Call spread in Praxair…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SYT

Syngenta

$92.65

0.05 (0.05%)

12:45
06/23/17
06/23
12:45
06/23/17
12:45
Periodicals
Syngenta ordered to pay $217.7M to Kansas farmers in GMO corn case, Reuters says »

A federal jury in Kansas…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MT

ArcelorMittal

$21.21

0.315 (1.51%)

12:45
06/23/17
06/23
12:45
06/23/17
12:45
Options
ArcelorMittal call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

12:45
06/23/17
06/23
12:45
06/23/17
12:45
General news
Breaking General news story  »

Week of 6/23 Baker-Hughes…

EFA

iShares MSCI EAFE Index Fund

$65.14

0.16 (0.25%)

, VEA

Vanguard Europe Pacific ETF

$41.22

0.089 (0.22%)

12:42
06/23/17
06/23
12:42
06/23/17
12:42
Technical Analysis
On The Fly: ETF fund flow highlights »

For the past week there…

EFA

iShares MSCI EAFE Index Fund

$65.14

0.16 (0.25%)

VEA

Vanguard Europe Pacific ETF

$41.22

0.089 (0.22%)

IEFA

iShares Core MSCI EAFE ETF

$60.83

0.135 (0.22%)

EWJ

iShares MSCI Japan Index Fund

$54.04

-0.05 (-0.09%)

EZU

iShares MSCI Eurozone ETF

$40.44

0.1 (0.25%)

IBB

iShares Nasdaq Biotechnology Index

$320.11

4.01 (1.27%)

IVV

iShares Core S&P 500

$246.13

0.53 (0.22%)

SPY

SPDR S&P 500 ETF Trust

$243.37

0.53 (0.22%)

VO

Vanguard Mid-Cap Index Fund

$143.23

0.561 (0.39%)

VTI

Vanguard Total Stock Market ETF

$125.10

0.36 (0.29%)

VUG

Vanguard Growth Index Fund

$128.93

0.421 (0.33%)

HYG

iShares iBoxx $ High Yield Corporate Bond

$88.11

0.265 (0.30%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PTLA

Portola Pharmaceuticals

$38.25

-1.24 (-3.14%)

12:33
06/23/17
06/23
12:33
06/23/17
12:33
Hot Stocks
Portola FDA label cites secondary endpoint instead of Cohort 1 data, tweet says »

Twitter user…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jun

  • 24

    Jun

VIX

Volatility Index S&P 500 Options

12:30
06/23/17
06/23
12:30
06/23/17
12:30
Options
VIX calls outpace puts nearly 5:1 as the index dips below 10 »

VIX calls outpace puts…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CZR

Caesars

$12.55

0.2 (1.62%)

, CACQ

Caesars Acquisition

$19.40

0.15 (0.78%)

12:29
06/23/17
06/23
12:29
06/23/17
12:29
Hot Stocks
Caesars announces effectiveness of S-4 registration statement related to merger »

Caesars Entertainment…

CZR

Caesars

$12.55

0.2 (1.62%)

CACQ

Caesars Acquisition

$19.40

0.15 (0.78%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GLYC

GlycoMimetics

$12.10

-0.03 (-0.25%)

12:28
06/23/17
06/23
12:28
06/23/17
12:28
Conference/Events
GlycoMimetics management to meet with Jefferies »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

GOOG

Alphabet

$957.09

-2.36 (-0.25%)

, GOOGL

Alphabet Class A

$976.62

-1.97 (-0.20%)

12:28
06/23/17
06/23
12:28
06/23/17
12:28
Hot Stocks
Google to bring Posts service to local businesses »

Alphabet's Google…

GOOG

Alphabet

$957.09

-2.36 (-0.25%)

GOOGL

Alphabet Class A

$976.62

-1.97 (-0.20%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

  • 28

    Jun

  • 28

    Jun

  • 19

    Jul

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.